社区居住老年退伍军人临终前有限获益药物的停用情况
该回顾性全国队列研究纳入37193名≥65岁、患有晚期限制生命疾病的社区居住非临终关怀退伍军人,73%在最后一年开始时使用至少一种有限获益药物,其中仅22.0%在最后一年内停用至少一种,78%持续使用至死亡。农村县停用率低于大城市县,中西部或南部高于东北部或西部,有有限预期寿命临床指标或接受专科姑息治疗者更可能停用。
要点
- 社区居住晚期疾病老年退伍军人中,73%在临终前一年起始使用至少一种有限获益药物。
- 基线有限获益药物使用者中仅22.0%在最后一年内停用至少一种,78%持续至死亡。
- 农村县停用率较低,中西部或南部高于东北部或西部,姑息治疗或有限预期寿命指标者更可能停用。
核心结论
- 社区居住老年退伍军人临终前一年有限获益药物使用普遍,但停用率低,多数持续至死亡。
- 该人群有限获益药物使用与停用模式与长期护理人群相似,提示社区医疗提供者需常规筛查并支持适当停用。
研究设计与样本
- 使用共识标准识别有限获益药物使用者,评估最后一年内停用情况,采用多变量稳健泊松回归估计停用率比。
主要发现
- 37193名死者中,73%在最后一年开始时(基线)使用至少一种有限获益药物(如他汀类、口服降糖药、降压药、抗血栓药、抗溃疡药或抗痴呆药)。
- 基线有限获益药物使用者中,22.0%在最后一年内经历至少一次有限获益药物停用。
- 居住在农村县者有限获益药物停用率低于大城市县者。
- 中西部或南部居民的停用率高于东北部或西部居民。
- 有记录显示有限预期寿命临床指标(如压力性溃疡、营养不良)或接受专科姑息治疗者更可能停用有限获益药物。
关键数值与推荐
- 有限获益药物通过共识标准识别,包括他汀类、口服降糖药、降压药、抗血栓药、抗溃疡药或抗痴呆药等类别。
- 基线有限获益药物使用者中22.0%在最后一年内停用至少一种有限获益药物,78%持续使用至死亡。
临床怎么用
- 社区医疗提供者应对晚期疾病和有限预期寿命老年患者常规筛查有限获益药物。
- 应支持适当停用有限获益药物,尤其关注农村地区及有有限预期寿命临床指标或接受姑息治疗的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Discontinuation of medications with limited benefits (LBM) in patients nearing the end of life can reduce burden, adverse events, and costs, and enhance quality of life. However, most research on end-of-life prescribing has focused on nursing homes or hospice settings. AIMS: To describe the prevalence of LBM use and discontinuation or deintensification over the last year of life in community-dwelling older veterans with advanced life-limiting conditions. DESIGN: Retrospective, national cohort study of U.S. veteran decedents (≥ 65 years) with advanced life-limiting conditions who died between October 2016 and September 2017. SETTING: Community-residing, non-hospice older veterans. LBM users were identified using consensus-based criteria and assessed for discontinuation over the last year of life. We estimated LBM discontinuation rate ratios using multivariable robust Poisson regression. RESULTS: Among 37,193 decedents (mean age 78 years), 73% were on at least one LBM (e.g., statins, oral antidiabetics, antihypertensives, antithrombotics, anti-ulcer, or antidementia drugs) entering the last year (baseline). Of these baseline LBM users, 22.0% experienced at least one LBM discontinuation over their final year. Veterans residing in more rural counties had lower LBM discontinuation rates than those in large metropolitan counties. Discontinuation rates were also higher in the Midwest or South compared to the Northeast or West. Veterans with documented clinical indicators of limited life expectancy (e.g., pressure ulcers, malnutrition) or those receiving specialty palliative care, were more likely to have LBMs discontinued. CONCLUSION: Among community-dwelling older veterans in their final year of life, 73% were receiving at least one LBM at the start of that year, and 78% of these individuals continued LBM use until death. These rates parallel those reported in long-term care populations and underscore the need for community-based healthcare providers to routinely screen for LBMs and support appropriate medication discontinuation in older patients with advanced illnesses and limited life expectancy.
引用
- Thorpe JM, Tran KA, Aspinall SL, et al. Discontinuation of Medications With Limited Benefit at End of Life in Community-Dwelling Older Veterans. J Am Geriatr Soc. 2026. PMID: 41925169. doi:10.1111/jgs.70381
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。